People with secondary progressive multiple sclerosis (SPMS) who began treatment with Mayzent early and continued its use for years are less likely to experience disability progression than those starting the medication later in their disease course, five-year data from the EXPAND study suggest.
Data from this same Phase 3 clinical trial further suggest that Mayzent can help preserve important tissues in the brain, delaying physical disability and slowing cognitive decline.
Mayzent (siponimod), developed by Novartis, is approved to treat active SPMS in both the United States and Europe. The oral therapy belongs to a class of medications called S1P receptor modulators. These work by ‘trapping’ immune cells in lymph nodes (immunological structures), which can limit the inflammation that causes nervous system damage in MS.
The Phase 3 EXPAND clinical trial (NCT01665144) is evaluating the safety and efficacy of Mayzent in people with SPMS. In the first part of this Novartis-sponsored study, participants were given either Mayzent or a placebo tablet for about three years. Results from this core part of the study, released in 2017, showed that Mayzent significantly slowed disability progression and cognitive decline compared to the placebo.
In its second part, 1,224 people continuing with the study entered an open-label extension phase, in which all were given the active treatment. New data cover this part of the trial.
In one abstract, “Long-term Efficacy and Safety of Siponimod in Patients with SPMS: EXPAND Extension Analysis Up to 5 Years,” researchers compared disability progression patterns between individuals who switched from placebo to Mayzent in the extension with those getting this treatment since EXPAND’s start. This comparison was to ascertain whether there were significant differences when treatment was started years earlier.
The analysis’ data covered up to five years of follow-up.
We are sorry that this post was not useful for you!
Let us improve this post!
Tell us how we can improve this post?